| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | RAS guanyl-releasing protein 2, Calcium and DAG-regulated guanine nucleotide exchange factor I, CalDAG-GEFI, Cdc25-like protein, hCDC25L, F25B33 kinase-like protein, RASGRP2, CDC25L, MCG7 |
| Entrez GeneID | 10235 |
| WB Predicted band size | 69.2kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This RASGRP2 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 108-142 amino acids from the N-terminal region of human RASGRP2. |
+ +
以下是关于RASGRP2 (N-term)抗体的示例参考文献(注：内容为模拟示例，非真实文献)：
---
1. **"RASGRP2 regulates platelet activation and thrombosis via CalDAG-GEFI signaling"**
*作者：Stefanini L. et al.*
**摘要**：研究利用RASGRP2 (N-term)抗体进行Western blot分析，发现RASGRP2缺陷小鼠的血小板中CalDAG-GEFI表达降低，揭示了其在血栓形成中的关键作用。
2. **"RASGRP2 modulates T-cell receptor signaling through interactions with Ras"**
*作者：Yang H. et al.*
**摘要**：通过免疫共沉淀(使用N-term抗体)和功能实验，证明RASGRP2通过激活Ras/MAPK通路调控T细胞活化，为自身免疫疾病机制提供新见解。
3. **"Structural insights into RASGRP2 N-terminal domain and its role in calcium signaling"**
*作者：Joseph R. et al.*
**摘要**：结合X射线晶体学和抗体标记(靶向N端)，解析了RASGRP2的N端结构域与钙离子结合的关系，阐明其信号传导的结构基础。
4. **"RASGRP2 expression correlates with leukemia progression and drug resistance"**
*作者：Bergmeier W. et al.*
**摘要**：采用RASGRP2 (N-term)抗体进行免疫组化，发现急性髓系白血病患者中RASGRP2高表达与化疗耐药性显著相关，提示其作为潜在治疗靶点。
---
以上内容为模拟生成，实际文献需通过学术数据库(如PubMed、Google Scholar)检索确认。
The RASGRP2 (N-term) antibody is a polyclonal or monoclonal antibody designed to target the N-terminal region of RAS Guanyl Releasing Protein 2 (RASGRP2), a key signaling molecule involved in regulating intracellular pathways. RASGRP2 belongs to the RASGRP family of guanine nucleotide exchange factors (GEFs) that activate small GTPases like RAS and RAP1 by promoting the exchange of GDP for GTP. Specifically, RASGRP2 plays a critical role in hematopoietic cells, including platelets and lymphocytes, where it mediates RAP1 activation to regulate integrin signaling, cell adhesion, and immune responses.
The N-terminal region of RASGRP2 contains conserved catalytic domains essential for its GEF activity, making it a common target for antibodies used in functional studies. Antibodies against the N-terminus are widely employed in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to detect RASGRP2 expression, localization, and post-translational modifications. They help investigate its role in physiological processes (e.g., platelet aggregation, immune cell activation) and pathological conditions, including bleeding disorders, immune deficiencies, or thrombosis.
Validation of RASGRP2 (N-term) antibodies typically includes testing in knockout models or siRNA-treated cells to confirm specificity. Dysregulation of RASGRP2 has been linked to diseases like leukocyte adhesion deficiency (LAD) and Glanzmann thrombasthenia, underscoring its biomedical relevance. Researchers rely on this antibody to explore RASGRP2-mediated signaling networks and potential therapeutic targets.
×
